Delivery device and delivery system for delivering therapeutic substance into blood vessel

Abstract

The utility model discloses a conveying device and a conveying system for conveying treatment substances into blood vessels, and the conveying device comprises an outer sheath which is of a tubular structure and is provided with a far end and a near end which are opposite to each other, and the outer sheath is internally provided with a treatment substance conveying channel; the tube assembly is movably arranged in the outer sheath; the retaining assembly is used for keeping the blood vessel at the expected therapeutic substance delivery position in an expanded state, and the retaining assembly adopts one of the following structures: a, a support frame which is of a radially deformable cylindrical structure as a whole and has a loading state in which the support frame can be accommodated in the outer sheath and an expanded state in which the support frame is exposed to the far end side of the outer sheath; the light-emitting component is fixed to the tube assembly, the light-emitting component is provided with a working part located in the expected conveying position of a treatment object, and the working part is used for outputting first light rays with the wavelength ranging from 400 nm to 1200 nm. The conveying device is better in blood vessel repairing effect.

Description

Technical Field

[0001] The present application relates to the field of medical device technology, and in particular to a delivery device and a delivery system for delivering therapeutic substances into blood vessels. Background Art

[0002] Cardiovascular diseases such as hypertension and coronary heart disease will cause vascular endothelial damage to patients. In order to repair vascular endothelial damage, various methods can be used. One of them is to deliver drugs to the site of endothelial damage through interventional means. The damaged site of vascular endothelium itself is prone to stenosis and is more likely to contract under the stimulation of drugs. Vascular repair under the condition of vascular contraction is not ideal. Utility Model Content

[0003] Based on this, an interventional therapeutic delivery device and delivery system are provided, which prevent blood vessels from contracting when delivering drugs to the site of endothelial damage, thereby improving the drug treatment effect.

[0004] A delivery device for delivering a therapeutic substance into a blood vessel, comprising:

[0005] an outer sheath, which is a tubular structure and has opposite distal and proximal ends, and an inner portion of the outer sheath has a therapeutic substance delivery channel;

[0006] a tube assembly movably disposed within the outer sheath;

[0007] A holding assembly is used to maintain the blood vessel at the intended delivery location of the therapeutic agent in an expanded state, wherein the holding assembly adopts one of the following structures:

[0008] a. A support frame, which is a radially deformable cylindrical structure as a whole, having a loaded state in which it can be accommodated in the outer sheath and an expanded state exposed to the distal side of the outer sheath;

[0009] b. A light-emitting component fixed to the tube assembly, wherein the light-emitting component has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400-1200 nm.

[0010] Several optional methods are also provided below, but they are not intended to be additional limitations on the above-mentioned overall solution. They are merely further supplements or optimizations. Under the premise that there are no technical or logical contradictions, each optional method can be combined separately for the above-mentioned overall solution, or multiple optional methods can be combined.

[0011] Optionally, it also includes:

[0012] The occlusion component includes a first balloon and a second balloon sequentially arranged along the axis of the outer sheath for temporarily blocking blood flow, and the area between the first balloon and the second balloon is the expected delivery position of the therapeutic substance.

[0013] Optionally, the first balloon is located at the periphery of the distal end of the outer sheath;

[0014] The second balloon, the distal end of the tube assembly has an extension portion extending out of the outer sheath, the second balloon is located on the periphery of the extension portion, and the first balloon and the second balloon are respectively located upstream and downstream of the expected delivery position of the therapeutic substance along the blood flow direction.

[0015] Optionally, a first fluid channel connected to the first balloon is provided in the side wall of the outer sheath for delivering fluid to the first balloon.

[0016] Optionally, the outer sheath is a double-layer tube structure and has an inner lumen and an outer lumen that are radially opposite to each other, wherein the inner lumen serves as a channel for the tube assembly, and the outer lumen separates and forms a first fluid channel for delivering fluid to the first balloon and a therapeutic substance delivery channel for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

[0017] Optionally, the cylindrical structure of the support frame is in the shape of a hollow grid.

[0018] Optionally, the tube assembly comprises:

[0019] an inner tube, wherein the lumen of the inner tube provides a guide wire passage;

[0020] The outer tube is sleeved on the outside of the inner tube, the distal end of the outer tube is connected to the second balloon, and the radial gap between the outer tube and the inner tube serves as a second fluid channel connected to the second balloon.

[0021] Optionally, the light-emitting component is an optical fiber or a Micro LED, and the light-emitting component is located in a radial gap between the inner tube and the outer tube.

[0022] Optionally, the conveying device as a whole has:

[0023] Working state, in which each balloon is inflated with fluid and exposed to the outer sheath, the support frame is exposed to the outer sheath and is in an expanded state, or the working portion of the light-emitting component is at the expected delivery position of the therapeutic substance and emits light;

[0024] Delivery state: in the delivery state, the balloons are folded and stored in the outer sheath, the support frame is stored in the outer sheath and is in a loading state, or the light-emitting component is stored in the outer sheath and does not emit light.

[0025] The present application also provides a delivery system for delivering a therapeutic substance into a blood vessel, comprising:

[0026] The conveying device;

[0027] a first perfusion device, configured to provide a therapeutic substance for delivery into the blood vessel and connected to the therapeutic substance delivery channel;

[0028] The second perfusion device is connected to the first balloon and the second balloon respectively through fluid pipelines.

[0029] The interventional therapeutic substance delivery device and delivery system provided in this application prevents blood vessels from contracting when delivering drugs to the site of endothelial damage, and performs drug treatment in a state of vascular dilation, resulting in better treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1a This is a schematic diagram of the therapeutic substance delivery device based on the interventional approach of the present application (the holding component uses a light-emitting component);

[0031] Figure 1b for Figure 1a A magnified view of part A in FIG;

[0032] Figure 2a Schematic diagram of the therapeutic substance delivery device based on the interventional approach of the present application (the holding component adopts a support frame);

[0033] Figure 2b for Figure 2a A magnified view of part B in FIG;

[0034] Figure 3 This is a schematic diagram of a first balloon and its supporting components in the interventional therapeutic delivery device of the present application;

[0035] Figure 4 for Figure 3 Enlarged view of part C in FIG;

[0036] Figure 5 This is a schematic diagram of the second balloon and its supporting components in the interventional therapeutic delivery device of this application (the holding component adopts a support frame);

[0037] Figure 6 for Figure 5 Enlarged view of part D in FIG;

[0038] Figure 7 A schematic diagram of one embodiment of a support frame;

[0039] Figure 8 This is a schematic diagram of the second balloon and its supporting components in the interventional therapeutic delivery device of this application (the retaining component uses a light-emitting component);

[0040] Figure 9 for Figure 8Enlarged view of part E in .

[0041] In the figure: 100, therapeutic delivery device; 110, outer sheath; 111, first fluid channel; 112, therapeutic delivery channel; 113, inner cavity; 114, outer cavity; 120, support frame; 130, tube assembly; 131, inner tube; 132, outer tube; 133, second fluid channel; 140, light-emitting component; 150, blocking assembly; 151, first balloon; 152, second balloon; 171, first handle; 1711, first interface; 1712, second interface; 1713, third interface; 172, second handle; 1721, fourth interface; 1722, fifth interface; 180, guidewire channel; 190, developing ring.

[0042] Y, distal; J, proximal. DETAILED DESCRIPTION

[0043] The following will be combined with the drawings in the embodiments of this application to clearly and completely describe the technical solutions in the embodiments of this application. Obviously, the embodiments described are only part of the embodiments of this application, not all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of this application.

[0044] In order to better describe and illustrate the embodiments of the present application, reference may be made to one or more drawings, but the additional details or examples used to describe the drawings should not be considered as limiting the scope of the invention of the present application, any of the currently described embodiments or preferred methods.

[0045] It should be noted that when a component is referred to as being "connected" to another component, it may be directly connected to the other component or there may be an intermediate component. When a component is referred to as being "disposed on" another component, it may be directly disposed on the other component or there may be an intermediate component.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application.

[0047] See also Figure 1a 、 Figure 1b 、 Figure 2a 、 Figure 2b As shown, the interventional therapeutic delivery device 100 includes:

[0048] The outer sheath 110 is a tubular structure having a distal end and a proximal end opposite to each other, and the interior of the outer sheath has a therapeutic substance delivery channel;

[0049] The tube assembly 130 is movably disposed in the outer sheath 110;

[0050] The occlusion assembly 150 includes a first balloon 151 and a second balloon 152 sequentially arranged along the axis of the outer sheath 110 for temporarily blocking blood flow, with the area between the first balloon 151 and the second balloon 152 being the intended delivery location for the therapeutic agent;

[0051] A holding component is used to maintain the blood vessel at the intended delivery location of the therapeutic agent in an expanded state, and the holding component adopts one of the following structures:

[0052] a. The support frame 120 is a radially deformable cylindrical structure as a whole, which has a loaded state in which it can be accommodated in the outer sheath 110 and an expanded state in which it is exposed to the distal side of the outer sheath 110 ( Figure 2a 、 Figure 2b The middle support frame is in the expanded state);

[0053] b. The light-emitting component 140 is fixed to the tube assembly 130. The light-emitting component 140 has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400-1200nm.

[0054] The therapeutic substance delivery device provided in the present application is used to deliver a therapeutic substance to a desired site. During the process of delivering the therapeutic substance, the blood vessels at the desired site may be narrowed, or may contract due to stimulation during the process of delivering the drug. In order to keep the blood vessels at the desired site in the necessary dilated state during the process of delivering the drug, a holding component is provided in the therapeutic substance delivery device. The holding component can adopt two structures, namely a support frame and a light-emitting component. Both structures can play the role of keeping the blood vessels in the dilated state, and only one of them can be selected. When the support frame and the light-emitting component are mentioned below, it is based on this premise, that is, the support frame and the light-emitting component do not exist at the same time, and only one of them can exist. Figure 1a 、 Figure 1b This is a schematic diagram of using a light-emitting component as a holding component. Figure 2a 、 Figure 2b Schematic diagram of using a support frame to retain the component.

[0055] When the retaining component is a support frame, the working process of the therapeutic substance delivery device provided in the present application is as follows:

[0056] During the delivery process, the support frame 120, the tube assembly 130 and the occluding assembly 150 are all housed in the outer sheath 110 (the support frame 120 is located in the radial gap between the tube assembly 130 and the outer sheath 110). After reaching the target site, the tube assembly 130 extends out of the outer sheath 110, and the support frame 120 is exposed at the distal end of the outer sheath 110, switching to an expanded state to support the blood vessels at the target site and deliver the therapeutic substance to the target site for treatment. During the treatment process, the support frame is always maintained in an expanded state. After the treatment is completed, the support frame 120 is not left in the target site for a long time, but is withdrawn from the blood vessels at the target site.

[0057] One of the structural forms of the support frame 120 is shown in FIG. Figure 7 As shown, the support frame 120 has a hollow grid structure, the support frame 120 is compressible in the radial direction, the distal end of the support frame 120 is an open structure, and the proximal end of the support frame 120 is bundled into a line and extends out of the proximal end of the outer sheath 110. The support frame 120 and the tube assembly 130 are not fixedly connected. During the delivery process, a movable connection can be set between the support frame 120 and the tube assembly 130 (for example, a protrusion is provided on the outer wall of the tube assembly to push the support frame 120 to move. The movable connection here is understood to mean that the two have a mutual force, rather than a substantial connection relationship), so that when the tube assembly 130 extends out of the outer sheath 110, it can drive the support frame 120 to be exposed to the outer sheath 110. On the distal end, when the support frame 120 is radially expanded and in an expanded state, the connection between the support frame 120 and the tube assembly 130 is disconnected. After the support frame 120 is released, the drug is delivered to the blood vessel at the intended location for treatment. During the treatment process, the first balloon 151 and the second balloon 152 can be withdrawn from the blood vessel at the target location first, leaving only the support frame 120 at the target location to prevent long-term obstruction of blood flow. At the same time, when the first balloon 151 and the second balloon 152 are withdrawn, since the support frame 120 still stays at the target location to play a supporting role, further damage to the inner wall of the blood vessel caused by the withdrawal of the first balloon 151 and the second balloon 152 can be avoided.

[0058] When the treatment is completed and the support frame 120 needs to be withdrawn, the sheath can be pushed onto the support frame 120. Under the force of the sheath, the support frame 210 radially contracts into the sheath, and the sheath drives the support frame 120 away from the target site.

[0059] When the holding component is a light-emitting component, the working process of the therapeutic substance delivery device provided by the present application is as follows:

[0060] During the delivery process, the light-emitting component 140, the tube assembly 130 and the blocking component 150 are all housed in the outer sheath 110. After reaching the target site, the tube assembly 130 extends out of the outer sheath 110. The light-emitting component 140 extends out of the outer sheath 110 along with the tube assembly 130, and applies a first light with a wavelength range of 400~1200nm to the blood vessel wall of the target site. The first light in this wavelength range has the effect of repairing the vascular endothelium and relaxing the smooth muscle. After the first light is applied for a certain period of time, the blood vessel wall can maintain an expanded state for a sufficient time, which can ensure that the blood vessel wall does not rebound during the delivery of the therapeutic agent. The first light also has the effect of repairing the vascular endothelium and can inhibit the occurrence of late vascular restenosis.

[0061] The blocking assembly 150 includes a first balloon 151 and a second balloon 152. In the working state, the first balloon 151 and the second balloon 152 are respectively located upstream and downstream of the blood flow direction to temporarily block the blood flow. Figure 1b 、 Figure 2b 、 Figure 3 、 Figure 4 As shown, the outer sheath 110 has a therapeutic delivery channel 112 inside; the occlusion assembly 150 includes:

[0062] The first balloon 151 is located on the periphery of the distal end of the outer sheath 110;

[0063] The second balloon 152 , the distal end of the tube assembly has an extension portion extending out of the outer sheath 110 , the second balloon 152 is located on the periphery of the extension portion, the first balloon 151 and the second balloon 152 are respectively located upstream and downstream of the intended delivery position of the therapeutic substance along the blood flow direction.

[0064] The first and second balloons 151, 152 are filled with fluid. When inflated, they temporarily block blood flow, creating a blood-free space between them, corresponding to the intended delivery location of the therapeutic agent. The order in which the first and second balloons 151, 152 are inflated depends on the direction of blood flow, with the balloons located further upstream inflated first to block blood flow.

[0065] See also Figure 3 、 Figure 4 As shown, a first fluid channel 111 is provided in the side wall of the outer sheath 110 and is in communication with the first balloon 151 for delivering fluid to the first balloon 151. The first fluid channel 111 extends along the axial direction of the outer sheath 110 to the proximal end of the outer sheath 110.

[0066] See also Figure 3 、 Figure 4As shown, a therapeutic substance delivery channel 112 is provided on the side wall of the outer sheath 110 , and the therapeutic substance delivery channel 112 extends axially to the proximal end of the outer sheath 110 , and the distal end of the therapeutic substance delivery channel 112 is open to deliver the drug to the intended delivery position of the therapeutic substance.

[0067] See also Figure 1a 、 Figure 2a 、 Figure 3 As shown, the proximal end of the outer sheath 110 is connected to a first handle 171 , which is provided with: a first interface 1711 connected to the first fluid channel 111 , a second interface 1712 for passing through the tube assembly 130 , and a third interface 1713 connected to the therapeutic delivery channel 112 .

[0068] See also Figure 1b 、 Figure 2b 、 Figure 4 As shown, the outer sheath 110 is a double-layer tube structure and has an inner lumen 113 and an outer lumen 114 that are radially opposite to each other, wherein the inner lumen 113 serves as a channel for the tube assembly 130, and the outer lumen 114 separates and forms a first fluid channel 111 for delivering fluid to the first balloon 151 and a therapeutic substance delivery channel 112 for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

[0069] The outer cavity 114 separates and forms the first fluid channel 111 and the therapeutic substance delivery channel 112 , that is, the first fluid channel 111 and the therapeutic substance delivery channel 112 are independent of each other. Part of the space of the outer cavity 114 serves as the first fluid channel 111 , and the other part of the space serves as the therapeutic substance delivery channel 112 .

[0070] See also Figure 4 As shown, a developing ring 192 is fixedly sleeved on the outer sheath 110 . The developing ring 192 is made of metal and can indicate the position of the first balloon 151 under the action of a developer.

[0071] The support frame 120 is made of memory material and switches from a loaded state to an expanded state by self-expansion after being exposed to the outer sheath 110. The structure of the support frame 120 can be in various forms, such as Figure 7 In the illustrated embodiment, the cylindrical structure of the support frame 120 is in the shape of a hollow grid.

[0072] See also Figure 5 As shown, the tube assembly 130 includes:

[0073] An inner tube 131 , wherein the lumen of the inner tube 131 provides a guidewire channel 180 ;

[0074] The outer tube 132 is sleeved on the outside of the inner tube 131, and the distal end of the outer tube 132 is connected to the second balloon 152. The radial gap between the outer tube 132 and the inner tube 131 serves as a second fluid channel 133 connected to the second balloon 152. The support frame 120 is located in the radial gap between the outer tube 132 and the outer sheath 110, and the proximal end of the support frame 120 is converged and extends out of the proximal end of the outer sheath 110.

[0075] When the support frame 120 is in the loading state ( Figure 5 、 Figure 6 The support frame 120 is shown in a loaded state), the support frame 120 and the outer tube 132 are simultaneously stored in the outer sheath 110. When the outer tube 132 extends out of the outer sheath 110, the support frame 120 moves out of the outer sheath 110 along with the outer tube 132, and the support frame 120 switches from the expansion state to the expanded state.

[0076] See also Figure 5 、 Figure 6 As shown, the proximal side of the tube assembly 130 is connected to the second handle 172 , and the second handle 172 is provided with a fourth interface 1721 connected to the guidewire channel 180 and a fifth interface 1722 connected to the second fluid channel 133 .

[0077] See also Figure 5 、 Figure 6 As shown, a developing ring 192 is fixed on the inner tube 131 . The developing ring 192 is made of metal and can indicate the position of the second balloon 152 under the action of a developer.

[0078] The distal end of the support frame 120 can slide relative to the outer tube 132. To prevent damage to the outer tube 132 wall caused by sliding of the distal end of the support frame 120, a support sleeve is slidably mounted on the outer circumference of the outer tube 132. The distal end of the support frame 120 is connected to the support sleeve. The support sleeve enables relative sliding between the distal end of the support frame 120 and the outer tube 132.

[0079] See also Figure 8 、 Figure 9 As shown, the light emitting component 140 is an optical fiber or a Micro LED, and is located in the radial gap between the inner tube 131 and the outer tube 132. The light emitting component 140 is fixed to the outer wall of the inner tube 131 and extends toward the proximal end along the second fluid channel 133.

[0080] When using optical fiber, a laser generator is required. When using Micro LED, a power supply is required. The power supply can use miniaturized components such as button batteries to make the overall balloon catheter device lightweight.

[0081] The wavelength of the first light is in the range of 600-850 nm. The wavelength of the first light affects the therapeutic effect, and preferred wavelengths include 635 nm, 650 nm, or 808 nm. The wavelength of the first light is not fixed during treatment and can be adjusted as the treatment progresses. For example, a shorter wavelength may be selected at the beginning of treatment, while a longer wavelength may be selected mid-way through treatment.

[0082] The therapeutic delivery device 100 generally comprises:

[0083] Working state: In the working state, each balloon (including the first balloon 151 and the second balloon 152) is inflated with fluid and exposed to the outer sheath 110, the support frame 120 is exposed to the outer sheath 110 and is in an expanded state, or the working portion of the light-emitting component 140 is at the expected delivery position of the therapeutic agent and emits light;

[0084] Delivery state. In the delivery state, each balloon (including the first balloon 151 and the second balloon 152) is folded in shape and housed in the outer sheath 110, the support frame 120 is housed in the outer sheath and is in a loading state, or the light-emitting component 140 is housed in the outer sheath 110 and does not emit light.

[0085] Working status see Figure 1a 、 Figure 1b 、 Figure 2a 、 Figure 2b As shown, Figure 1a 、 Figure 1b 、 Figure 2a 、 Figure 2b The first balloon 151 and the second balloon 152 are inflated with fluid, and the support frame 120 is in an expanded state and both are exposed to the outer sheath 110 .

[0086] The present application also provides a delivery system for delivering a therapeutic substance into a blood vessel, comprising:

[0087] The therapeutic substance delivery device 100 of the present application;

[0088] a first perfusion device, for providing a therapeutic substance to be delivered into the blood vessel, and communicating with the therapeutic substance delivery channel 112;

[0089] The second perfusion device is connected to the first balloon 151 and the second balloon 152 respectively through fluid pipelines.

[0090] The first balloon 151 and the second balloon 152 can be connected to the same second perfusion device through a fluid pipeline. The perfusion of the first balloon 151 and the second balloon 152 can be independently controlled. Alternatively, the first balloon 151 and the second balloon 152 can be equipped with their own perfusion devices.

[0091] The therapeutic substance delivered into the blood vessels includes pentagalloylglucose, which is a phenolic compound with multiple phenolic groups. In the body, pentagalloylglucose can cross-link elastin in blood vessels to stabilize the blood vessels.

[0092] The present application also provides a method for deploying a vascular therapeutic agent, comprising:

[0093] Temporarily block blood flow upstream and downstream of a designated area along the blood flow direction;

[0094] Expand at a designated site where a vascular therapeutic substance is expected to be delivered to maintain the spatial shape of the designated site;

[0095] Releases therapeutic substances to the designated area and maintains the predetermined treatment time.

[0096] First, a blocking component is used to temporarily block blood flow upstream and downstream of a designated area where a vascular therapeutic substance is expected to be delivered. Second, a support frame or a light-emitting component is used to dilate the blood vessel. Finally, the therapeutic substance is delivered to the designated area.

[0097] A support frame or light-emitting component is used to dilate the blood vessels to keep them in the necessary dilated shape, and then a therapeutic substance is delivered into the blood vessels. The vascular therapeutic substance is pentagalloylglucose, which can cross-link the elastin in the blood vessels.

[0098] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0099] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art could make various modifications and improvements without departing from the spirit of the present application, all of which fall within the scope of protection of the present application. Therefore, the scope of protection of the present patent application shall be determined by the appended claims.

Claims

1. A delivery device for delivering a therapeutic substance into a blood vessel, characterized in that: include: an outer sheath, which is a tubular structure and has opposite distal and proximal ends, and an inner portion of the outer sheath has a therapeutic substance delivery channel; a tube assembly movably disposed within the outer sheath; A holding assembly is used to maintain the blood vessel at the intended delivery location of the therapeutic agent in an expanded state, wherein the holding assembly adopts one of the following structures: a. A support frame, which is a radially deformable cylindrical structure as a whole, having a loaded state in which it can be accommodated in the outer sheath and an expanded state exposed to the distal side of the outer sheath; b. A light-emitting component fixed to the tube assembly, wherein the light-emitting component has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400-1200 nm.

2. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 1, characterized in that: Also includes: The occlusion component includes a first balloon and a second balloon sequentially arranged along the axis of the outer sheath for temporarily blocking blood flow, and the area between the first balloon and the second balloon is the expected delivery position of the therapeutic substance.

3. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 2, characterized in that: The first balloon is located at the periphery of the distal end of the outer sheath; The second balloon, the distal end of the tube assembly has an extension portion extending out of the outer sheath, the second balloon is located on the periphery of the extension portion, and the first balloon and the second balloon are respectively located upstream and downstream of the expected delivery position of the therapeutic substance along the blood flow direction.

4. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 3, characterized in that: A first fluid channel communicating with the first balloon is provided in the side wall of the outer sheath for delivering fluid to the first balloon.

5. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 3, characterized in that: The outer sheath is a double-layer tube structure and has an inner cavity and an outer cavity opposite to each other in the radial direction, wherein the inner cavity serves as a channel of the tube assembly, and the outer cavity separates and forms a first fluid channel for delivering fluid to the first balloon and a therapeutic substance delivery channel for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

6. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 1, characterized in that: The cylindrical structure of the support frame is in the shape of a hollow grid.

7. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 2, wherein: The tube assembly comprises: an inner tube, wherein the lumen of the inner tube provides a guide wire passage; The outer tube is sleeved on the outside of the inner tube, the distal end of the outer tube is connected to the second balloon, and the radial gap between the outer tube and the inner tube serves as a second fluid channel connected to the second balloon.

8. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 7, characterized in that: The light-emitting component is an optical fiber or a Micro LED, and the light-emitting component is located in a radial gap between the inner tube and the outer tube.

9. The delivery device for delivering a therapeutic substance into a blood vessel according to claim 3, characterized in that: The conveying device as a whole has: Working state, in which each balloon is inflated with fluid and exposed to the outer sheath, the support frame is exposed to the outer sheath and is in an expanded state, or the working portion of the light-emitting component is at the expected delivery position of the therapeutic substance and emits light; Delivery state: in the delivery state, the balloons are folded and stored in the outer sheath, the support frame is stored in the outer sheath and is in a loading state, or the light-emitting component is stored in the outer sheath and does not emit light.

10. A delivery system for delivering a therapeutic substance into a blood vessel, characterized in that: include: The conveying device according to any one of claims 1 to 9; a first perfusion device, configured to provide a therapeutic substance for delivery into the blood vessel and connected to the therapeutic substance delivery channel; The second perfusion device is connected to the first balloon and the second balloon respectively through fluid pipelines.

Images